VENUS REMEDIES
Back to Income Statement
|
VENUS REMEDIES Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹653 Cr | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr |
What is the latest Revenue of VENUS REMEDIES ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹653 Cr |
| Mar2025 | ₹601 Cr |
| Mar2024 | ₹556 Cr |
| Mar2023 | ₹600 Cr |
| Mar2022 | ₹548 Cr |
How is Revenue of VENUS REMEDIES Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹653 Cr | 8.55 | |
| Mar2025 | ₹601 Cr | 8.27 | |
| Mar2024 | ₹556 Cr | -7.44 | |
| Mar2023 | ₹600 Cr | 9.50 | |
| Mar2022 | ₹548 Cr | - | |
Compare Revenue of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹2,041.6 Cr | -1.5% | -12.2% | 200.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -2.6% | 2.4% | 14.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹221,666.0 Cr | 6.5% | 23.3% | 25.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,108.0 Cr | 2.6% | 3% | 33.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.1% | -0.2% | -7.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,990.9 Cr | 2.6% | -13.3% | -10.7% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -1.5% |
-12.2% |
200.9% |
| SENSEX | 1.2% |
0.4% |
-2.9% |
You may also like the below Video Courses